文献速递肿瘤 PET/CT核素与放射性配体治疗

140Nd/140Pr体内PET发生器用于HER2靶向药物的临床前评估

Evaluation of the In Vivo PET Generator 140Nd/140Pr Using a HER2-Targeting Agent.
PubMed 文献 · J Nucl Med · 2026-09-30

本研究评估了140Nd/140Pr体内PET发生器偶联HER2靶向单克隆抗体的可行性与临床前性能。140Nd通过141Pr(p,2n)反应生产,分别用DOTA和MACROPA螯合剂标记曲妥珠单抗。DOTA偶联物稳定性高、靶向特异性强、肿瘤摄取持续,支持该发生器作为抗体诊疗的PET成像平台。

要点

  • 140Nd/140Pr体内发生器可作为f区治疗核素的PET成像类似物。
  • [140Nd]Nd-DOTA-trastuzumab稳定性高且HER2靶向特异性强。
  • [140Nd]Nd-MACROPA-trastuzumab在血清中解离明显,肿瘤摄取低。

核心结论

  • [140Nd]Nd-DOTA-trastuzumab具有优异稳定性、HER2特异性靶向和持续肿瘤摄取,支持140Nd/140Pr体内发生器作为抗体诊疗PET成像平台的可行性。

研究设计与样本

  • 采用141Pr(p,2n)140Nd反应在 cyclotron facility 生产高纯度140Nd,并经DGA基分离法纯化。
  • 将曲妥珠单抗偶联pSCN-Bn-DOTA或SCN-MACROPA螯合剂后用140Nd标记,评估放射化学产率、稳定性和体外细胞摄取。
  • 在HER2阳性BT474与阴性MDA-MB-468荷瘤模型中进行PET/CT显像与离体生物分布。

主要发现

  • [140Nd]Nd-DOTA-trastuzumab和[140Nd]Nd-MACROPA-trastuzumab的放射化学产率均>95%,比活度分别为74.0 kBq/µg和114.7 kBq/µg。
  • [140Nd]Nd-DOTA-trastuzumab在PBS、生理盐水、小鼠血清和人血清中7 d内保持>95%完整。
  • [140Nd]Nd-MACROPA-trastuzumab在PBS和生理盐水中保持>95%完整,但在小鼠和人血清中显著解离。
  • 两种示踪剂在HER2阳性BT474细胞中的摄取显著高于HER2阴性MDA-MB-468细胞及HER2阻断的BT474细胞(P<0.0001)。
  • [140Nd]Nd-DOTA-trastuzumab在7 d时HER2阳性肿瘤SUVmean为4.90±0.66,阴性肿瘤为0.69±0.11;离体分布HER2阳性肿瘤摄取从24 h的26.08±3.93 %ID/g升至7 d的48.87±22.18 %ID/g,阴性肿瘤为11.52±0.71至10.54±1.00 %ID/g。

临床怎么用

  • 临床前数据显示[140Nd]Nd-DOTA-trastuzumab适合作为HER2靶向抗体诊疗的PET显像剂进一步开发。
  • MACROPA螯合剂因血清解离导致肿瘤摄取低,不推荐用于该体内发生器体系。

局限性

  • 研究为临床前评估,尚未在人体中验证。
  • MACROPA偶联物的低肿瘤摄取可能与体内解离有关,但未进一步阐明机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Theranostic strategies using targeted radiopharmaceuticals frequently use f-block therapeutic radionuclides, such as 225Ac, 177Lu, and 161Tb; however, there are limited PET imaging counterparts within this chemical space. The in vivo PET generator pair 140Nd (half-life, 3.4 d; electron capture)/140Pr (half-life, 3.4 min; 51.0% β+) represents a promising imaging analog for these therapeutic radionuclides. The purpose of this study was to assess the feasibility and preclinical performance of the 140Nd/140Pr in vivo generator using a human epidermal growth factor receptor 2 (HER2)-targeted monoclonal antibody. High-purity 140Nd was produced via the 141Pr(p,2n)140Nd reaction at the University of Alabama at Birmingham cyclotron facility and purified using an in-house diglycolamide-based separation method. Trastuzumab was conjugated with pSCN-Bn-DOTA or SCN-MACROPA chelators and radiolabeled with 140Nd to generate [140Nd]Nd-DOTA-trastuzumab or [140Nd]Nd-MACROPA-trastuzumab. Radiolabeling of DOTA-trastuzumab and MACROPA-trastuzumab with 140Nd achieved quantitative radiochemical yields of greater than 95% corresponding to specific activity of 74.0 kBq/µg (2.0 μCi/µg) and 114.7 kBq/µg (3.1 μCi/µg), respectively. [140Nd]Nd-DOTA-trastuzumab remained more than 95% intact in phosphate-buffered saline, saline, mouse serum, and human serum for up to 7 d. [140Nd]Nd-MACROPA-trastuzumab remained more than 95% intact in phosphate-buffered saline and saline but showed significant decomplexation in mouse and human sera. Both radiotracers demonstrated significantly higher uptake in HER2-positive BT474 cells than in HER2-negative MDA-MB-468 cells (P < 0.0001) and HER2-blocked BT474 cells. PET/CT imaging with [140Nd]Nd-DOTA-trastuzumab demonstrated substantial tumor accumulation in HER2-positive tumors (SUVmean, 4.90 ± 0.66 at 7 d) compared with HER2-negative tumors (SUVmean, 0.69 ± 0.11 at 7 d). Ex vivo biodistribution supported the imaging findings, with HER2-positive tumor uptake increasing from 26.08 ± 3.93 %ID/g to 48.87 ± 22.18 %ID/g between 24 h and 7 d, whereas HER2-negative tumors showed lower uptake (11.52 ± 0.71 %ID/g to 10.54 ± 1.00 %ID/g). In contrast, [140Nd]Nd-MACROPA-trastuzumab exhibited minimal tumor accumulation in both models, as demonstrated by PET/CT (SUVmean at 7 d: HER2-positive, 0.49 ± 0.10; HER2-negative, 0.14 ± 0.06) and biodistribution analysis (4.60 ± 1.40 %ID/g vs. 3.63 ± 0.77 %ID/g, respectively), likely attributable to in vivo decomplexation. These results demonstrate that [140Nd]Nd-DOTA-trastuzumab exhibits excellent stability, HER2-specific targeting, and sustained tumor uptake, supporting the feasibility of the 140Nd/140Pr in vivo generator as a PET imaging platform for antibody-based theranostic applications.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Godara ML, Tekin V, Houson HA, et al. Evaluation of the In Vivo PET Generator 140Nd/140Pr Using a HER2-Targeting Agent. J Nucl Med. 2026. PMID: 42816127. doi:10.2967/jnumed.126.272952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。